MARKET

GPCR

GPCR

Structure Therapeutics Inc ADR
NASDAQ
50.17
+1.97
+4.09%
Pre Market: 52.11 +1.94 +3.86% 04:33 04/02 EDT
OPEN
49.46
PREV CLOSE
48.20
HIGH
52.47
LOW
48.84
VOLUME
51
TURNOVER
0
52 WEEK HIGH
94.90
52 WEEK LOW
13.22
MARKET CAP
3.55B
P/E (TTM)
-21.0339
1D
5D
1M
3M
1Y
5Y
1D
What's Going On With Structure Therapeutics Stock On Wednesday?
Benzinga · 14h ago
BUZZ-Eli Lilly rises after US FDA approves weight-loss pill
Reuters · 16h ago
Weekly Report: what happened at GPCR last week (0323-0327)?
Weekly Report · 2d ago
Structure Therapeutics: A High-Risk, High-Reward Bet On The Next GLP-1 Blockbuster
Seeking Alpha · 5d ago
NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now?
NASDAQ · 03/23 14:53
Weekly Report: what happened at GPCR last week (0316-0320)?
Weekly Report · 03/23 09:09
LifeSci Capital Keeps Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)
TipRanks · 03/21 14:56
Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Structure Therapeutics, Inc. Sponsored ADR (GPCR) and Lifecore Biomedical (LFCR)
TipRanks · 03/17 13:30
More
About GPCR
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.

Webull offers Structure Therapeutics Inc (ADR) stock information, including NASDAQ: GPCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GPCR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GPCR stock methods without spending real money on the virtual paper trading platform.